Sofia Bisso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sofia Bisso has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Christophe Leroux
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich 8093 Zurich, Switzerland
2 shared publications Anna Degrassi
B Department of Biology , Nerviano Medical Sciences Srl , Milan , Italy
1 shared publicationBastien Castagner
Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada
1 shared publicationDavide Brambilla
A Department of Chemistry and Applied Biosciences , Institute of Pharmaceutical Sciences, ETH Zurich , Zurich , Switzerland
1 shared publicationPatrick Couvreur
Institut Galien Paris-Sud, UMR 8612, CNRS, Université Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry cedex, France
1 shared publicationSimona Mura
Institut Galien Paris-Sud, UMR 8612, CNRS, Université Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry cedex, France
1 shared publication
Latest Publications
- 1 September 2019
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 142, 142-152
Dual delivery of nucleic acids and PEGylated-bisphosphonates via calcium phosphate nanoparticles
- 1 September 2019
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 142, 142-152
Dual delivery of nucleic acids and PEGylated-bisphosphonates via calcium phosphate nanoparticles
- Open Access
- 4 December 2018
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 27 (5-6) , 659-669
Poly(ethylene glycol)-alendronate coated nanoparticles for magnetic resonance imaging of lymph nodes
Nanoparticulate systems can passively target regional lymphatic vessels and lymph nodes (LNs) after interstitial administration. Highly sensitive non-invasive imaging techniques, such as magnetic resonance imaging (MRI), can take advantage from particles’ lymphotropic properties to provide a reliable tool to monitor lymphatic function and LN morphology with high spatial resolution. In this work, we developed and characterised a bioerodible nanosystem with MRI contrast properties, based on poly(ethylene glycol)-alendronate stabilised gadolinium calcium phosphate nanoparticles (NPs). After foot paw injection in mice, the particles exhibited a distinct pattern of gradual uptake into the local lymphatics and a localised deposition in the popliteal LN. Less variability in the onset of the signal, intensity and localisation was observed compared to the commercially available tracer gadobutrol, suggesting that these NPs could be useful to monitor physiological and dysfunctional lymphatic conditions. Moreover, dissolution of the particles indicated that they would be rapidly cleared from the body after imaging. Nevertheless, our findings call for an improvement of the system that includes reduction of gadolinium leakage from the NPs, and decrease in size of the latter to increase their selective uptake by the LN.
- 4 December 2018
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 27 (5-6) , 659-669
Open AccessPoly(ethylene glycol)-alendronate coated nanoparticles for magnetic resonance imaging of lymph nodes
Nanoparticulate systems can passively target regional lymphatic vessels and lymph nodes (LNs) after interstitial administration. Highly sensitive non-invasive imaging techniques, such as magnetic resonance imaging (MRI), can take advantage from particles’ lymphotropic properties to provide a reliable tool to monitor lymphatic function and LN morphology with high spatial resolution. In this work, we developed and characterised a bioerodible nanosystem with MRI contrast properties, based on poly(ethylene glycol)-alendronate stabilised gadolinium calcium phosphate nanoparticles (NPs). After foot paw injection in mice, the particles exhibited a distinct pattern of gradual uptake into the local lymphatics and a localised deposition in the popliteal LN. Less variability in the onset of the signal, intensity and localisation was observed compared to the commercially available tracer gadobutrol, suggesting that these NPs could be useful to monitor physiological and dysfunctional lymphatic conditions. Moreover, dissolution of the particles indicated that they would be rapidly cleared from the body after imaging. Nevertheless, our findings call for an improvement of the system that includes reduction of gadolinium leakage from the NPs, and decrease in size of the latter to increase their selective uptake by the LN.